Axitinib, Free Base
Axitinib (AG013736, trade name Inlyta is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal models and has shown partial responses in clinical trials with renal cell carcinoma(RCC) and several other tumour types. It was approved by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival, though there have been reports of fatal adverse effects.
Cancer Research and Antivirals
|Appearance||white to off white crystalline solid|
Send us your enquiry for Axitinib, Free Base. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Axitinib, Free Base email us and we will include your contribution on the website.